Introduction
============

Chronic pancreatitis (CP) is characterized by fibro-inflammation, and it is often associated with chronic pain.[@b1-jpr-10-1347] As the disease progresses, exocrine and endocrine insufficiency may develop,[@b2-jpr-10-1347],[@b3-jpr-10-1347] necessitating treatment with antidiabetic medication and enzymatic supplementation. While these aforementioned complications are relatively straightforward to treat, chronic pain is more challenging and is associated with reduced quality of life and increased health resource utilization.[@b4-jpr-10-1347]--[@b6-jpr-10-1347] In the patients where the underlying pathology is not amenable to endoscopic intervention or surgery, the treatment of pain is largely pharmacological in nature.[@b7-jpr-10-1347] Analgesic monotherapy rarely provided meaningful analgesic relief and combination therapy, such as opioids and gabapentoids are therefore often needed. However, adverse effects secondary to opioids are common, and therefore, achieving a balance between analgesic benefits and such side effects is challenging, particular in patients with other complications such as duodenal stenosis, pseudocysts and ongoing pancreatic inflammation. Notwithstanding the adverse cognitive effects of opioids, they may further compromise gastrointestinal (GI) function with diminution of motility.[@b8-jpr-10-1347],[@b9-jpr-10-1347] Therefore, there is a pressing unmet clinical need for the development of effective alterna-tives, which ameliorate pain and enhance GI motility in CP.

Normal GI function relies on a bidirectional communication from the gut to the central nervous system, delivered in part by the autonomic nervous system (ANS). The ANS consists of two broadly opposing branches referred to as the sympathetic and the parasympathetic nervous systems,[@b10-jpr-10-1347] which integrate with the enteric nervous system in the gut. The vagus nerve forms the main parasympathetic neural substrate of the ANS, while the spinal afferents form the sympathetic nerves.[@b11-jpr-10-1347] Thus, in health, there is a delicate balance between sympathetic and parasympathetic influences, which is responsible for release of hormones, GI motility and the maintenance of homeostasis. A paucity of vagal activity has been identified as a pathophysiological feature in a number of disorders related to the GI tract including inflammatory bowel disease, functional dyspepsia, irritable bowel syndrome and diabetic autonomic neuropathy and gastroparesis.[@b12-jpr-10-1347]--[@b15-jpr-10-1347] In CP, preliminary studies have postulated that autonomic dysfunction may contribute to the complex pain and GI dysmotility.[@b16-jpr-10-1347]--[@b18-jpr-10-1347] Vagal activity can be therapeutically accentuated either physiologically, with deep slow breathing (DSB), or electrically, using vagus nerve stimulation (VNS), which can be applied invasively or noninvasively through the skin. In healthy volunteers, DSB and noninvasive transcutaneous electrical vagal nerve stimulation (t-VNS) of the auricular branch of the vagus nerve have been shown to decrease experimental pain and increase GI motility.[@b19-jpr-10-1347],[@b20-jpr-10-1347] Hence, combined physiological and electrical modulation of vagal tone, using DSB and t-VNS, respectively, may represent an alternative non-pharmacological treatment modality for pain and GI dysmotility in CP. We hypothesized that by increasing parasympathetic tone, with combined DSB and VNS, sensory processing of pain would be modulated and gastroduodenal motility enhanced in comparison to sham stimulation and sham breathing. The aims of the study were to study patients with CP to evaluate the effects of parasympathetic modulation using DSB and t-VNS on 1) experimental musculoskeletal pain thresholds, 2) descending pain modulation and 3) gastroduodenal motility.

Patients and methods
====================

Study oversight
---------------

This was a randomized, single-blinded, sham-controlled, crossover study conducted at the research laboratories of Mech-Sense at the Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark. All patients provided written informed consent after oral and written information and adequate consideration. The North Denmark Region Committee on Health Research Ethics approved the study (N-20090008).

Patients
--------

Twenty patients were recruited from the outpatient clinic of our institution. Participants were eligible if diagnosed with CP according to the Mayo Clinic Diagnostic Criteria and aged 18--75 years.[@b21-jpr-10-1347] Other chronic pain conditions, pregnancy and allergies to any equipment of the trials (e.g., latex gloves, electrodes) were regarded as exclusion criteria. Individual patient's analgesic treatment regimens were not altered during the study, and rescue medication for pain flare-ups was allowed.

Randomization and blinding
--------------------------

Patients were randomly assigned to receive 60 minutes of t-VNS during which they undertook 2 × 10 minutes of DSB, or sham procedure, in a crossover design. Randomization was employed using a randomization list generated at [randomization.com](http://randomization.com). Patients were told that they would receive two different forms of nerve stimulation at different locations on the ear. Investigators were not blinded to stimulation sequence (i.e., single-blinded study). Patients were fasted for at least 6 hours prior to each study visit. Visits were planned at identical hours of the day and with an interval of minimum 7 days to reduce any potential carryover effect.[@b22-jpr-10-1347] The study protocol is illustrated in [Figure 1](#f1-jpr-10-1347){ref-type="fig"}.

Outcomes measures
-----------------

There were no specific thresholds predetermined due to the exploratory nature of study. The outcome measures were merged, as this was an explorative study. Pain was assessed using 1) quantitative sensory testing (QST) to document changes in pain sensitivity assessed by pressure pain thresholds in bone and muscle and 2) changes in descending pain modulation capacity using a conditioned pain modulation (CPM) paradigm.[@b17-jpr-10-1347],[@b19-jpr-10-1347] Finally, gastroduodenal motility parameters were assessed using 3) a modified version of a real-time ultrasonography method to demonstrate changes in motility pattern following a standardized drink test.[@b23-jpr-10-1347]

Study procedures
----------------

An overview of the experimental protocol is provided in [Figure 2](#f2-jpr-10-1347){ref-type="fig"}.

### VNS

Noninvasive transcutaneous electrical VNS of the auricular branch of the vagal nerve was performed using a commercially available device (Nemos^®^; cerbomed GmbH, Erlangen, Germany). A bipolar stimulation electrode was connected to a pocketsize stimulator, and the electrode was placed in the left concha. The skin was cleaned with an alcohol wipe (Alkoholswabs; Mediq Danmark A/S, Brøndby, Denmark) to ensure a sufficient skin contact was made between the electrode and the skin. The stimulation intensity was individually adjusted (described later) and ranged from 0.1 mA to 10 mA with a pulse width of 250 μs and a stimulation frequency of 30 Hz. At baseline, patients were familiarized to the stimulus for 5 minutes prior to the experimental procedures, where the intensity was slowly increased until the optimal intensity was reached (i.e., a painful tingling sensation). Due to habituation, the intensity was readjusted throughout the study visit. The aim of the stimulation was continuous stimulation at the level of the intensity of the initial perceptive experience. For sham t-VNS, the device was turned 180°, stimulating the outer earlobe that does not contain parasympathetic fibers.[@b24-jpr-10-1347] Patients received t-VNS, or sham equivalent, for a total of 60 minutes.

### Breathing protocol

Physiological vagal stimulation was undertaken with a validated deep breathing protocol, consisting of breathing at full inspiratory capacity for 4 seconds, followed by exhaling to forced expiratory vital capacity for 6 seconds, repeated at a frequency of 0.1 Hz (i.e., six breaths per minute).[@b20-jpr-10-1347] For the sham breathing procedure, patients were asked to breathe normally and count their breaths. Patients undertook two sessions of 10 minutes of DSB, or sham equivalent, at two epochs during the study, i.e., at 15 minutes and 30 minutes.

Experimental procedures
-----------------------

### ANS Monitoring

Electrocardiogram (ECG) electrodes (Ambu^®^ BlueSensor P; Ambu A/S, Copenhagen, Denmark) were attached at the right and left sub-clavicular areas and over the cardiac apex. Systolic blood pressure, diastolic blood pressure and mean blood pressure were continuously recorded using a photoplethysmographic sensory cuff (Nexfin^®^; BMEYE B.V., Amsterdam, the Netherlands) attached to the right third digit.[@b25-jpr-10-1347],[@b26-jpr-10-1347] The ECG was recorded using a commercially available biosignals acquisition system (Neuroscope™; Medifit Instruments Limited, Enfield, England; Portapres^®^; Finapres Medical Systems BV, Amsterdam, the Netherlands). Based on an R-wave detection algorithm, beat-to-beat, R-R interval and heart rate were computed. Cardiac vagal tone (CVT) was computed beat-to-beat based on detecting positive phase shifts in the R-R interval, a process called "phase-shift demodulation". CVT is measured on a validated linear vagal scale, where 0 represents full atropinization and is a putative measure of efferent vagal activity. The Neuroscope also derives cardiac sensitivity to the baroreflex (CSB) through the incorporation of beat-to-beat R-R intervals with mean blood pressure into a 10-second cyclical and is considered to be an indirect measure of PNS afferent activity.

### QST

Muscle and bone pain pressure thresholds were assessed at baseline and after 10 minutes and 25 minutes of intervention. Assessments were made on the right quadriceps muscle and the tibia bone. A handheld electronic pressure algometer (Algometer; Somedic SenseLab AB, Hörby, Sweden) was used with a probe surface area of 1 cm^2^ for muscle stimulation and 3 mm^2^ for bone stimulation. Pressure was increased at a rate of 30 kPa/s until the moderate pain threshold was reached (i.e., a score of 7 on a 11-point visual analog scale, ranging from 0 to 10).[@b27-jpr-10-1347] The patients were instructed to notify the investigators when reaching the moderate pain threshold, and the corresponding pressure stimulation intensity (kPa) was noted. The muscle pressure was also used as the test stimulus before, during and after induction of CPM (described later).

### CPM

The capacity of descending pain modulation was assessed after 40 minutes of intervention using a validated CPM paradigm (REF). CPM is a clinically measurable form of descending pain modulation that can be induced experimentally by a conditioning stimulus and quantified by applying a "test-pain" before and after its induction. Normally, there is a 30%--40% fall in the pain evoked by the test stimulus after the conditioned stimulation.[@b17-jpr-10-1347],[@b28-jpr-10-1347] We used the cold pressor test for conditioning and somatic pressure stimulation of the quadriceps muscle as test stimulus.

### Cold pressor test

The right hand was immersed in cold water (2.0°C±0.3°C) continuously stirred by a pump. The patients were told to remove the hand from the water after 2 minutes of immersion or earlier if the pain was intolerable. If a patient withdrew his/her hand due to intolerable pain prior to this 120 seconds mark, the data were still included, as it was considered that descending pain control had been induced due to the intensity of the conditioning stimulus.[@b17-jpr-10-1347]

### Pressure stimulation (test stimulus)

The moderate pressure pain threshold was determined on the quadriceps muscle 5 cm proximal to the patella using the pressure probe described earlier. Pressure thresholds were assessed before, during (90 seconds) and 2 minutes and 5 minutes after the cold pressor test.[@b19-jpr-10-1347] The differences in pain thresholds before and after induction of cold pressor pain provide a quantitative index of the CPM capacity.

### Evaluation of gastroduodenal motility parameters

Assessment of gastroduodenal motility was performed after 50 minutes of intervention. A powdered tomato soup (Knorr^®^ Cup-a-Soup tomato; Unilever, Heilbronn, Germany) provided the basis of the liquid meal used for the drink test. Ten grams of powdered soup with an energy content of 35 kcal (1 g fat, 6 g carbohydrates, 0.5 g dietary fibers, 1.25 g protein and 0.75 g salt) was dissolved in 400 mL of boiled water. The soup was served at a temperature of 40°C. Patients were asked to consume the soup over 2 minutes via a straw to reduce any associated air swallowing. A modified validated version of a real-time ultrasonography method previously described by Kusunoki et al[@b19-jpr-10-1347],[@b23-jpr-10-1347] was used for gastroduodenal motility parameters. The superior mesenteric vessels and the left liver lobe were used as landmarks to obtain a standardized sagittal ultrasonic view. For ultrasound investigations, a scanner (MyLab™70 XVision; Esaote S.p.A., Genoa, Italy) with a standard abdominal probe (CA631; Esaote S.p.A.) was used. The patients were instructed in shallow breathing during ultrasonography. Still images were stored at baseline (fasting state) and after 1 minute and 15 minutes postprandial at relaxed state. Using in-built tool within the scanner, a free-hand tracing of the mucosal line of the antrum was used for the estimate of antral cross-section areas (CSAs). The gastric emptying rate (GER) was defined as $$\text{GER} = \frac{(\text{antral~CSA~at~minute} - \text{antral~CSA~at}\ 15\ \text{minutes}) \times 100}{\text{antral~CSA~at}\ 1\ \text{minute}}$$

The frequency of antral contractions was defined as the number of contractions within a 3-minute interval obtained during shallow breathing within the first 5 minutes postprandial. This 3-minute interval was recorded and analyzed offline avoiding CSA measurements during inspiration. The amplitude of antral contractions was calculated from the maximal reduction in CSAs and included the mean of three full contractions during the 3-minute interval: $$\text{Amplitude} = \frac{(\text{CSA~relaxed} - \text{CSA~contracted}) \times 100}{\text{CSA~relaxed}}$$

The motility index (MI) was defined as the mean amplitude multiplied by the frequency of antral contractions per 3 minutes: $$\text{MI} = \text{amplitude}_{\text{mean}} \times \text{frequency}_{3\ \text{minutes}}$$

Statistical analyses
--------------------

All data are presented as mean±standard deviation (SD) unless otherwise indicated. Paired Student's test or Wilcoxon signed-rank tests were used to analyze cardiac-derived parameters, QST parameters and gastroduodenal motility parameters; results of within-group analysis and between-group analysis are reported. Bonferroni corrections were applied for multiple comparisons. A *P*-value \<0.05 was considered statistically significant. The software package STATA version 14.1 (StataCorp LP, College Station, TX, USA) was used for statistical calculations.

Results
=======

All 20 enrolled patients completed the study. Patients' demographic and clinical characteristics are reported in [Table 1](#t1-jpr-10-1347){ref-type="table"}. The ultrasonographic results of six participants were excluded from the analysis of gastroduodenal motility parameters due to air ingestion resulting in inadequate visualization of the antrum. No adverse events were reported for sham or active t-VNS.

ANS parameters
--------------

All cardiac-derived parameters are reported in [Table 2](#t2-jpr-10-1347){ref-type="table"}. Compared to sham stimulation, an increase in CVT was seen after t-VNS (3.9±2.3 vs. 6.2±4.8; *P*=0.02) ([Figure 3](#f3-jpr-10-1347){ref-type="fig"}). Furthermore, the mean blood pressure was significantly lowered during t-VNS compared to baseline (86.4±15.5 mmHg vs. 81.6±16.0 mmHg; *P*=0.046), while no significant effect on diastolic blood pressure was observed.

QST
---

QST parameters are reported in [Table 2](#t2-jpr-10-1347){ref-type="table"}. Compared to sham stimulation, t-VNS induced no demonstrable differences in muscle pressure thresholds (989±336 kPa vs. 991±342 kPa; *P*=0.97) or bone pressure thresholds (161±63 kPa vs. 170±88 kPa; *P*=0.67). Also, no differences in thresholds were observed between patients on opioids vs. no opioids.

CPM
---

Prior to the conditioning stimulus (CPM baseline), the pressure pain thresholds were comparable between active and sham-stimulated patients (967±274 kPa vs. 887±284 kPa; *P*=0.37). However, a diminished CPM response was seen after t-VNS when compared to sham stimulation (7.6±22.5% vs. 26.6±18.8%; *P*=0.02) ([Figure 4](#f4-jpr-10-1347){ref-type="fig"} and [Table 2](#t2-jpr-10-1347){ref-type="table"}).

Gastroduodenal motility parameters
----------------------------------

No significant changes in gastroduodenal motility parameters were observed between t-VNS and sham stimulation: gastric emptying rate (36.2±33.8% vs. 23.4±48.4%; *P*=0.55), frequency of antral contractions (4.9±2.4 per 3 minutes vs. 4.6±3.0 per 3 minutes; *P*=0.69), amplitude of antral contractions (42.4±17.3% vs. 42.1±18.5%; *P*=0.96) and MI (no unit) (4.9±3.6 vs. 4.5±3.3; *P*=0.31).

Discussion
==========

We have provided evidence that in patients with CP, acute combined electrical and physiological modulation of vagal tone results in an increase in cardiometrically derived parameters of vagal tone in comparison to sham stimulation. However, this increase was not associated with any alterations in experimental somatic pain sensitivity or gastroduodenal motility parameters. In addition, a reduction in descending inhibition was seen during vagal stimulation as compared to the sham procedure.

The effects of intervention
---------------------------

### Vagal activation

Thus, the key result of this study was that t-VNS was able to increase the cardiometrically derived parameters of parasympathetic activity in patients with a potentially sensitized pain system.[@b17-jpr-10-1347],[@b29-jpr-10-1347],[@b30-jpr-10-1347] In a previous multicenter study of healthy subjects, the normal range for CVT was defined as 1.9--17.8.[@b25-jpr-10-1347] In another study of patients with functional chest pain of presumed esophageal origin, the patients had lower CVT at baseline (5.5±0.84 vs. 11.76±1.6) in comparison to healthy subjects. By comparison with these studies, our patients had an even lower baseline CVT at baseline, thereby potentially indicating the existence of an underlying vagal neuropathy.

### Motility

Hitherto, t-VNS has not been investigated in patients with CP. In a recent study of healthy volunteers, t-VNS increased MI and the frequency of antral contractions compared to sham stimulation,[@b19-jpr-10-1347] although this was not an effect that we saw in this study. In part, this may be a consequence of the concomitant analgesic treatment in our patient cohort as well as the chronic neuronal changes in patients with CP, whereby neural plasticity has been demonstrated both peripherally and centrally.[@b16-jpr-10-1347],[@b31-jpr-10-1347],[@b32-jpr-10-1347] In relation to gastroduodenal motility assessment, temporal properties and intensity of the t-VNS may also play a role with different impact on the vagal tone, and other modalities of VNS may be used in future trials.

### Pain

The combined effect of acute t-VNS and DSB was insufficient to induce an analgesic effect arguably in patients with an already chronically sensitized pain system. During the recent past, a considerable research effort has been afforded to investigate the analgesic potential of VNS.[@b33-jpr-10-1347] Traditionally, it is thought that visceral pain afferent information is primarily conducted via spinal afferents although there is an increasing appreciation that the ANS is involved in pain genesis in maintenance across a number of chronic pain syndromes including CP.[@b16-jpr-10-1347],[@b18-jpr-10-1347],[@b34-jpr-10-1347] Of note, Botha et al[@b20-jpr-10-1347] demonstrated that physiological accentuation of vagal tone, using DSB, could prevent the development of acid-induced esophageal hypersensitivity in a validated model in healthy volunteers. Moreover, it was shown that the analgesic effect of DSB could be abolished with coadministration of the vagolytic agent atropine. In another study of healthy volunteers investigating t-VNS, experimental somatic pain thresholds increased with short-lasting-t-VNS of the auricular branch of the vagal nerve.[@b19-jpr-10-1347] The analgesic effect of VNS is postulated to be mediated through stimulation of afferent vagal nerve fibers projecting centrally to the nucleus tractus solitarius, raphe magnus, locus coeruleus, amygdala and periaqueductal gray. All these areas in the central nervous system are involved in the descending inhibitory modulation of pain, via the neurotransmitter gamma-aminobuytric acid (GABA).[@b35-jpr-10-1347] Hence, the failure to induce pain attenuation in this cohort may be due to aberrant central plasticity and/or malfunction within the pain system particularly as previous studies of patients with CP have shown diminished CPM compared to healthy volunteers.[@b17-jpr-10-1347],[@b29-jpr-10-1347] The diminished CPM effect during VNS compared to sham stimulation was an unexpected finding. In animal studies, it has been suggested that during diabetic neuropathy and central sensitization, the GABAergic effect can shift from inhibitory to excitatory leading to disinhibition.[@b36-jpr-10-1347] If this is the case, in a subpopulation of these patients having expectedly central sensitization due to chronic pain, the unexpected finding of diminished CPM may be partly explained. If this is the case, the increased parasympathetic tone should then activate the GABAergic system, which due to disinhibition responds conversely. Based on these present findings, it remains uncertain whether the findings are as consequences of peripheral and/or central nervous system changes in this cohort of patients with CP.[@b32-jpr-10-1347]

Methodological considerations and study limitations
---------------------------------------------------

CP represents a heterogeneous group of patients, with different pathophysiology and a variable number of coexisting diagnoses such as diabetes and different analgesic treatments, which evolves with disease duration.

Therefore, the inclusion of patients with both painful (n=14) and non-painful CP (n=6) may have influenced the results of this study and further investigations of an exclusive cohort of patients with painful CP, i.e., presumed sensitized pain system, may be of relevance for design of future studies. We wanted, however, to investigate CP patients, with functioning nervous system, and therefore, the investigated patients only had a mean duration of CP of 92.4 months ([Table 1](#t1-jpr-10-1347){ref-type="table"}), as we suspected that CP patients with chronic pain would have a more complex and sensitized pain system.

Although this study enhanced parasympathetic tone, there was no change in any of the algometric end points, thereby suggesting that the analgesic potency of the short-term t-VNS may not have been powerful enough to induce clinical effects in CP patients with a potentially chronic sensitized pain system. Otherwise, structural changes in the nervous system due to CP, neuroinflammation due to coexisting diabetes and the complex nature of CP including several parallel mechanisms behind the pain and dysmotility could likely influence the outcome. Therefore, other more potent modalities such as cervical t-VNS with multiple stimulations, could potentially be considered for future studies. Finally, as our design did not allow assessment of the physiological or the electrical stimulation individually, different approaches, e.g., multiple study arms, may be advantageous in the future.

In relation to ultrasound recordings, intra-observer variance may apply. We, however, aimed to reduce this potential bias, as specialists in radiology JBF or AM supervised all procedures that were all undertaken by the same operator JJ.[@b19-jpr-10-1347] Furthermore, patient instruction was imperative, as the procedure needs delicate time managements and focus on not consuming air concomitant with ingestion of the soup. Some patients, however, did ingest air, which in time obscured the visualization of the antrum during analyses of gastroduodenal motility parameters in six patients. Other authors experienced similar problems in healthy volunteers, even in the pioneering study by Kusunoki et al.[@b19-jpr-10-1347],[@b23-jpr-10-1347] This may imply that exclusion of patients may easily occur, in particular in patients with already impaired gut function, e.g., CP; hence, future trials should take this into consideration and power the study for potential dropouts due to impaired visualization of the antrum.

Conclusion
==========

This study provides evidence that t-VNS may serve as a potential modulator of the parasympathetic nervous system in patients with CP. However, in this study, short-term neuromodulation was not sufficient to affect musculoskeletal pain pressure sensitivity and gastroduodenal motility parameters. This could be due to the complex pathophysiology of CP pain and dysmotility, including peripheral neuropathy, central sensitization and plasticity in central pain processing. Future trials in CP are likely to necessitate longer periods of neuromodulation and potentially should be conducted as a possible add-on to existing analgesic treatment.
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![Study protocol.\
**Abbreviations:** t-VNS, noninvasive transcutaneous electrical vagal nerve stimulation; DSB, deep slow breathing; SB, sham breathing.](jpr-10-1347Fig1){#f1-jpr-10-1347}

![Experimental procedures.\
**Abbreviations:** QST, quantitative sensory testing; CPM, conditioned pain modulation; t-VNS, noninvasive transcutaneous electrical vagal nerve stimulation; DSB, deep slow breathing; SB, sham breathing.](jpr-10-1347Fig2){#f2-jpr-10-1347}

![Changes in cardiac-derived parameters boxplot.\
**Notes:** Median and upper and lower quantiles shown. Whiskers represent minimum and maximum. Dots represent outliers.](jpr-10-1347Fig3){#f3-jpr-10-1347}

![Changes in pain pressure thresholds.\
**Abbreviations:** PPT, pressure pain threshold; CP, cold pressor test of 120 seconds.](jpr-10-1347Fig4){#f4-jpr-10-1347}

###### 

Demographic and clinical characteristics of patients

  Variables                                                        Values
  ---------------------------------------------------------------- -------------------
  Male, n (%)                                                      12 (60)
  Mean age in years (range)                                        60.7 (50--78)
  Duration of CP in months (range)                                 92.4 (9--249)
  Painful CP (duration of pain \>12 weeks), n (%)                  14 (70)
  Non-painful CP, n (%)                                            6 (30)
  Etiology, n (%)                                                  
   Toxic/metabolic                                                 11 (55)
   Idiopathic                                                      3 (15)
   Genetic                                                         0 (0)
   Autoimmune                                                      1 (5)
   Recurrent                                                       1 (5)
   Obstructive                                                     4 (20)
  BMI (kg/m^2^)                                                    23.7 (18.8--36.9)
  Diabetes mellitus, n (%)                                         
   NIDDM                                                           3 (15)
   IDDM                                                            6 (30)
  Ongoing alcohol abuse, n (%)                                     0 (0)
  Current smoker, n (%)                                            13 (65)
  Analgesics, n (%)                                                
   NSAIDs/paracetamol                                              14 (70)
   Tramadol/codeine                                                8 (40)
   Opioids                                                         7 (35)
   Adjuvants (tricyclic antidepressants, gabapentin, pregabalin)   3 (15)
  Opioid equivalents in mg (range)                                 33.0 (0--120)
  Rescue medication, n (%)                                         
   Strong opioids                                                  9 (45)
   Weak opioids and/or paracetamol                                 5 (25)
  Complications to CP, n (%)                                       11 (55)
   EPI                                                             
   Pseudocysts                                                     4 (20)
   Bile duct obstruction                                           2 (10)
   Duodenal stenosis                                               0 (0)
   Splenic vein thrombosis                                         0 (0)

**Abbreviations:** CP, chronic pancreatitis; BMI, body mass index; NIDDM, non-insulin-dependent diabetes mellitus; IDDM, insulin-dependent diabetes mellitus; NSAIDs, non-steroid anti-inflammatory drugs; EPI, exocrine pancreatic insufficiency.

###### 

Cardiac-derived parameters and QST in CP patients before and after vagal tone modulation (deep breathing combined with t-VNS) and sham stimulation

  Test modality                             Parameter (unit)                       Baseline                                                Vagal tone modulation   Baseline                                                   Sham modulation                                             *P*-value[a](#tfn3-jpr-10-1347){ref-type="table-fn"}
  ----------------------------------------- -------------------------------------- ------------------------------------------------------- ----------------------- ---------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------
  Cardiac-derived parameters                Heart rate (beats/min)                 74.6±12.3                                               74.7±10.7               72.5±11.8                                                  69.7±10.1[\*\*\*](#tfn6-jpr-10-1347){ref-type="table-fn"}   0.0004
  Cardiac vagal tone (linear vagal scale)   3.6±2.2                                6.2±4.8[\*\*](#tfn5-jpr-10-1347){ref-type="table-fn"}   4.1±2.3                 3.9±2.3                                                    0.02                                                        
  Diastolic blood pressure (mmHg)           70.2±14.3                              64.0±19.6                                               68.3±13.9               67.3±14.0                                                  0.36                                                        
  Systolic blood pressure (mmHg)            118.8±21.1                             114.7±20.7                                              111.7±20.8              120.6±23.4[\*\*](#tfn5-jpr-10-1347){ref-type="table-fn"}   0.18                                                        
  Mean blood pressure (mmHg)                86.4±15.5                              81.6±16.0[\*](#tfn4-jpr-10-1347){ref-type="table-fn"}   82.7±15.7               85.1±15.5                                                  0.21                                                        
  Quantitative sensory testing              Muscle pressure pain threshold (kPa)   939±237                                                 991±342                 972±81                                                     989±336                                                     0.97
  Bone pressure pain threshold (kPa)        155±57                                 170±88                                                  989±336                 161±63                                                     0.67                                                        
  Cold pressor test (seconds)               --                                     80±47                                                   --                      85±46                                                      0.14                                                        
  CPM (%)                                   --                                     7.6±22.5                                                --                      26.6±18.8                                                  0.02                                                        

**Notes:** Data presented as mean ± SD.

Vagal tone modulation vs. sham modulation (between-group analysis). Significance of the difference between baseline and vagal tone/sham modulation (within-group analysis);

*P*\<0.05;

*P*\<0.01;

*P*\<0.001.

**Abbreviations:** QST, quantitative sensory testing; CP, chronic pancreatitis; VNS, vagal nerve stimulation; CPM, conditioned pain modulation.
